Results 191 to 200 of about 184,582 (277)

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. [PDF]

Br J Cancer
Besse A, Sedlarikova L, Buechler L, Kraus M, Yang CH, Strakova N, Soucek K, Navratil J, Svoboda M, Welm AL, Joerger M, Driessen C, Besse L.   +12 more
europepmc   +1 more source

Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. [PDF]

Sci Rep, 2020
Bulut H, Hattori SI, Aoki-Ogata H, Hayashi H, Das D, Aoki M, Davis DA, Rao KV, Nyalapatla PR, Ghosh AK, Mitsuya H.   +10 more
europepmc   +1 more source

Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. [PDF]

J Mol Graph Model, 2021
Prashantha CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, Suraj V, Sahana KV, Sujana HS, Guruprasad NM, Ramachandra R.   +10 more
europepmc   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability. [PDF]

Antimicrob Agents Chemother
Mulato A, Lansdon E, Aoyama R, Voigt J, Lee M, Liclican A, Lee G, Singer E, Stafford B, Gong R, Murray B, Chan J, Lee J, Xu Y, Ahmadyar S, Gonzalez A, Cho A, Stepan GJ, Schmitz U, Schultz B, Marchand B, Brumshtein B, Wang R, Yu H, Cihlar T, Xu L, Yant SR.   +26 more
europepmc   +1 more source

Sensing HIV Protease and Its Inhibitor Using "Helical Epitope"-Imprinted Polymers. [PDF]

Sensors (Basel), 2020
Chou CY, Lin CY, Wu CH, Tai DF.
europepmc   +1 more source

Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans-In Silico, In Vitro and In Vivo Approaches. [PDF]

J Fungi (Basel), 2021
Santos ALS, Braga-Silva LA, Gonçalves DS, Ramos LS, Oliveira SSC, Souza LOP, Oliveira VS, Lins RD, Pinto MR, Muñoz JE, Taborda CP, Branquinha MH.   +11 more
europepmc   +1 more source

When Viruses Talk through Extracellular Vesicles: a New Perspective on Sars‐Cov‐2‐Induced Neurodegeneration

Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.
ABSTRACT SARS‐CoV‐2 infection is linked to persistent neurological symptoms Post‐Acute Sequelae SARS‐CoV‐2 (neuro‐PASC) and elevated risk of neurodegenerative disease, but molecular events connecting acute viral injury to long‐term CNS dysfunction remain unclear.
Gunjan Bawne, Loet Coenen, Erik Nutma, Jinte Middeldorp, Magdalena J. Lorenowicz   +4 more
wiley   +1 more source

HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon. [PDF]

BMC Infect Dis
Nzengui-Nzengui GF, Mourembou G, M'boyis-Kamdem H, Kombila-Koumavor AC, Ndjoyi-Mbiguino A.   +4 more
europepmc   +1 more source

Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors. [PDF]

J Mol Struct, 2021
Cardoso WB, Mendanha SA.
europepmc   +1 more source